News Updates

More Articles Back to Article

Sanofi announces price cut for two insulin products

Sanofi announced that it will reduce the list price of its most-prescribed insulin product Lantus in the US by 78% and Apidra by 70%, with out-of-pocket monthly costs to be capped at $35 for those with private insurance. The price change will be effective Jan. 1. CNBC (3/16)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!